Poor ROI for GenAI
We recorded 5 claims from this post. 2 were checked against evidence. 3 can’t be checked. Read the post at its source.
Claims from this post (5)
In the order they appear in the post. Each quotation is the speaker’s words in this post. A label such as “Supported” or “Can’t be checked” is the claim’s current assessment; its page has the evidence and the reasons.
Assessment: UnresolvedSaid
“NVidia is down significantly more this year (23.4%) than the S&P (11.5%).”
What we tested: NVidia's stock is down 23.4% in 2025 so far, significantly more than the S&P's 11.5% decline.
Assessment: Can’t be checkedSaid
“One reason may be that it is starting to become clear that GenAI is not delivering the ROI (return on investment) people expected.”
What we tested: NVidia's sharp stock decline may be partly because it is becoming clear that GenAI is not delivering the expected return on investment.
Assessment: Can’t be checkedSaid
“With “GPT-5” level models remaining elusive, this picture may not change enormously in the near-term.”
What we tested: With GPT-5-level models still elusive, the poor ROI picture for GenAI may not change enormously in the near term.
Assessment: Can’t be checkedSaid
“With “GPT-5” level models remaining elusive, this picture may not change enormously in the near-term.”
What we tested: As of April 2025, GPT-5-level models have not yet arrived.
Assessment: SupportedSaid
“GenAI is pitched as (near) AGI, but reliability problems persist, limiting how well it can be used in practice.”
What we tested: Although GenAI is marketed as near-AGI, its reliability problems persist and limit how well it can be used in practice.
What happened: This is primary evidence of a prominent supplier promoting progress toward AGI. It supports the promotional premise, not the proposition that any existing product actually was AGI. (Sam Altman, OpenAI CEO, )